Beam Therapeutics BEAM Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $139.74M+120% | $63.52M-83.2% | $377.71M+520% | $60.92M+17.5% | ||
| $409.62M+11.4% | $367.56M-16.0% | $437.38M+40.4% | $311.59M-19.5% | ||
| $113.82M+2.1% | $111.53M-4.5% | $116.81M+33.0% | $87.81M+53.4% | ||
| $523.44M+9.3% | $479.09M-13.6% | $554.19M+38.8% | $399.4M-10.1% | ||
| -$383.69M+7.7% | -$415.57M— | —— | -$338.48M+13.8% | ||
| -274.6%+380pp | -654.3%— | —— | -555.6%+201pp | ||
| $304.64M+684% | $38.87M-14.3% | $45.32M-42.1% | $78.3M+240% | ||
| —— | -$14.09M+24.2% | -$18.59M-192% | $20.2M— | ||
| —— | -$376.74M— | —— | -$289.09M+22.0% | ||
| —— | -$4.58— | —— | -$4.13+30.1% | ||
| —— | -$4.58— | —— | -$4.13+30.1% | ||
| 391.4M+19.1% | 328.7M+7.9% | 304.8M+9.1% | 279.3M+10.4% | ||
| 391.4M+19.1% | 328.7M+7.9% | 304.8M+9.1% | 279.3M+10.4% | ||
| —— | -$1.62M+83.4% | -$9.74M— | —— | ||
| —— | -$376.67M— | —— | -$291.47M+21.4% | ||
| $1.64M-31.7% | $2.4M— | —— | $23.9M+376% | ||
| $43.73M-10.9% | $49.09M+5.2% | $46.68M+205% | $15.3M— | ||
| $139.74M+120% | $63.52M-83.2% | $377.71M+520% | $60.92M+17.5% | ||
| -$383.69M+7.7% | -$415.57M— | —— | -$338.48M+13.8% | ||
| -$361.4M+8.2% | -$393.64M— | —— | -$324.33M+15.8% | ||
| -$361.4M+8.2% | -$393.64M— | —— | -$324.33M+15.8% | ||
| -258.6%+361pp | -619.7%— | —— | -532.4%+210pp | ||
| -$383.69M+7.7% | -$415.57M— | —— | -$338.48M+13.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Beam Therapeutics's income statement data come from?
- Every line is extracted from Beam Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.